Novartis announced that Kymriah (tisagenlecleucel), its CD19-directed CAR-T therapy, failed to reach the primary endpoint in the Phase III BELINDA trial in patients with aggressive…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.